“HHS should consider using march-in rights when drugs face limited competition or market practices have failed to ensure an affordable price, ensuring that prescription drugs invented with taxpayer dollars are reasonably priced and affordable.”
Washington Post rated this: Lacks context
Washington Post says: This remains a theory. No administration or court has ever accepted this reasoning.